The Medical Letter on Drugs and Therapeutics
Statin Label Changes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Citing some recent reports, the FDA has announced changes in the safety labeling of all HMG-CoA reductase inhibitors (statins).1

HEPATOTOXICITY — Routine monitoring of hepatic enzymes is no longer recommended. Serious hepatic injury has been rare, and monitoring was not helpful in detecting or preventing it. Liver function tests should be performed before starting a statin and, if there is a clinical indication, during therapy.

LOVASTATIN DRUG INTERACTIONS — New contraindications, drug interactions and dosing recommendations were added to the lovastatin (Mevacor, and others) prescribing information. These are similar to the recent changes in the labeling for simvastatin (Zocor, and others).2

COGNITIVE PROBLEMS — The labeling of all statins will now mention rare post-marketing ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Statin Label Changes
Article code: 1386a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian